ClinicalTrials.gg
RecruitingNCT07154056FORASTIMUpdated Feb 17, 2026

Evaluation of the Efficacy of STNS With FAST and MULTIWAVE in Patients With Refractory Chronic Neuropathic Pain

An interventional study of Lead(s) and Implantable Pulse Generator implantation in Chronic Neuropathic Pain, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.

Planned enrollment
89th of 102
17 · median 62
Started
2026
with 10 others
No phase
46 of 132
23 open now
Primary completion
2027-02
later than 13 of 39 live
Registered
121st of 132
by date

Among the 132 studies in Neuralgia with a site in France, this one is the 89th largest by planned enrollment of the 102 interventional ones that give a count, is one of 11 that started in 2026, is one of 46 with no phase, reaches primary completion later than 13 of the 39 other live ones, and was the 121st registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Neuralgia with a site in France, or all of them as a file.
02

Study summary

The goal of the study is to demonstrate Spinal Transforaminal NeuroStimulation effectiveness with FAST and other waveforms / combinations to relief neuropathic peripheral pain in chronic neuropathic pain patients, at low risk and low energy consumption.

03

Conditions studied

  • Chronic Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subject has ≥ 18 years and ≤ 80 years
  • Subject has a global Visual Analogic Scale ≥ 5
  • Subject has non-cancer pain with a significant neuropathic component for at least 6 months.
  • Subject has stable pain for at least 30 days
  • Pain medication(s) dosage(s) is/are stable for at least 30 days
  • Subject is eligible for Spinal Transforaminal NeuroStimulation after a pre-implantation assessment by a multidisciplinary team, as described by the French National Authority for Health (Haute Autorité de Santé)
  • Subject understands and accepts the constraints of the study and is able to use the equipment.
  • Patient is covered by French national health insurance.
  • Subject has given written consent to the study after having received clear and complete information.

Non-inclusion Criteria:

  • Subject has a coagulation disorder
  • Subject is or has been treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system
  • Subject has had therapy within the past 30 days
  • Subject has had radiofrequency therapy within the past 3 months
  • Subject has been diagnosed with cancer in the past 2 years
  • Subject has had a spinal surgery within the past 6 months
  • Simultaneous participation to any interventional study on health product or any study able to interfere with the current study endpoints.
  • Subject has at least one of brain MRI such as : intracranial clips /Vascular clips/Pace maker/Heart battery, Defibrillator, Implanted Holter (REVEAL type), Neuro-stimulator not compatible with 1.5 T MRI/Stents/ Coils/Cardiac valves (heart)/ Shunt valve/Implanted injection pump/Cochlear implants/Implantable chamber (PAC)/Intracorporeal metal shards/ metallic foreign bodies, the location and the presence of implanted neurostimulation components that are not listed as MRI Conditional, cardiac implantable electronic device, metallic intraocular foreign bodies, cochlear implants, drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing.
  • Subjects requiring closer protection, i.e. minors, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patients in an emergency setting
  • Pregnant or breastfeeding women, women at age to procreate and not using effective .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (estimated)

Study arms

  • Experimental
    Lead(s) implantation, 7days trial phase, Implantable Pulse Generator implantation

    One or two 8-contact lead(s) will be radiologically positioned within the spinal foramen under awake anesthesia in order to optimize paresthesia coverage. This will be followed by a trial phase for a period of 7 days in order to assess the benefits of stimulation. Patients who succeeded the trial phase (at least 30% reduction of leg pain measured with a 5-day pain diary) will be implanted with a permanent system (Implantable Pulse Generator). At first, all patients will be programmed under FAST stimulation for at least 24h to fully perceive its efficacy. If the patient is satisfied with FAST then the patient will continue with this program but if the patient is not satisfied, then the patient could switch to other waveforms that will be pre-programmed during the visit including conventional and microburst stimulation.

    Device: Lead(s) and Implantable Pulse Generator implantation

Interventions

  • DeviceLead(s) and Implantable Pulse Generator implantation

    8-contact lead(s) will be radiologically positioned within the spinal foramen under awake anesthesia in order to optimize paresthesia coverage. Awake anesthesia will allow patients to be tested during the surgery in order to determine the sweet spot and the optimal paresthesia coverage using the PREDI-P platform for a single lead. A trial phase will be performed for a period of 7 days in order to assess the benefits of stimulation according to the HAS (French Health Authority) guidelines. Subjects who succeed the lead trial will receive a permanent implant depending on the patient electrical consumption during the lead trial period or according to the implanter decision.

06

What researchers measure

Primary outcomes

  1. The primary outcome for evaluating pain-related health is the mean absolute change in Multidimensional Clinical Response Index.

    The Multidimensional Clinical Response Indexwas previously developed and validated to evaluate the pain-related health state of PSPS-T2 patients. This weighted composite outcome includes pain intensity, functional disability, quality of life, psychological distress and pain mapping surface. The Multidimensional Clinical Response Indexis a score that ranges from 0 (worst pain-related health status) to 10 (best pain-related health status). The score has been used in several studies evaluating efficacy of different neurostimulation modalities.

    Time frame: 6 months

Secondary outcomes

  1. Absolute change in pain intensity between baseline and 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation follow-up.

    Will be used : Pain Visual Analogic Scale (VAS). Pain intensity is measured on a 0-10 scale (0 = no pain ; 10 = worst possible pain).

    Time frame: 6 months

  2. Evaluation of patient satisfaction at 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation.

    Patient satisfaction will be assessed using patient Global Impression of Change questionnaire (PGIC).

    Time frame: 6 months

  3. To evaluate the effects of Spinal Transforaminal NeuroStimulation on neuropathic pain symptoms.

    Evaluation of intensity of each symptom (numbness, burning sensation, tingling, allodynia, electric shock, hypoesthesia) using the PainDetect questionnaire.

    Time frame: 6 months

  4. Surface (cm²) of each symptom calculated using the Pain mapping software.

    To evaluate the effects of Spinal Transforaminal NeuroStimulation on neuropathic pain symptoms.

    Time frame: 6 months

  5. To characterize the Spinal Transforaminal NeuroStimulation neural targeting based on 3D-imaging and electrophysiological exploration in order to precisely identify the optimal paresthesia-based neural target locations.

    Imaging data (3D-MRI and CT fusion) pre-operatively to identify the ganglion position related to the foramen at baseline. For electrophysiological data, we will collect lead performance and selectivity for each program used by the patient under paresthesia-based stimulation at 1-, 3- and 6-month follow-ups.

    Time frame: 6 months

  6. Rate of serious and non-serious adverse events and device deficiencies will be reported.

    Time frame: 6 months

  7. Rate of patients undergoing FAST stimulation (exclusively or in combination with other waveforms) at 6-month follow-up.

    Time frame: 6 months

  8. Mean absolute change in Multidimensional Clinical Response Index for the subgroup of patients undergoing FAST at 1-, 3- and 6-month follow-ups.

    Time frame: 6 months

  9. Absolute change in pain surface between baseline and 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation follow-up.

    Pain surface will be assessed using the surface of the painful zone (cm²) measured using the pain mapping software.

    Time frame: 6 months

  10. Absolute change in health related quality of life between baseline and 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation follow-up.

    Health related quality of life will be assessed using EuroQuol 5 Dimensions 5 levels (EQ5D 5L) index (-0.53 to 1 score ; 1 = full health and 0 = a state as bad as being dead).

    Time frame: 6 months

  11. Absolute change in functional disability between baseline and 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation follow-up.

    Functional disability will be assessed using the Oswestry Disability Index (ODI) (0 to 100 score with 0-20 = minimal disability, 21-40 = moderate disability, 41-60 = severe disability, 61-80 = cripple, pain impinges on all aspects of patient's life, 81-100 = patients are bed-bound or exaggerating their symptoms).

    Time frame: 6 months

  12. Absolute change in anxiety and depression between baseline and 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation follow-up.

    Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS) anxiety and depression scores.

    Time frame: 6 months

  13. Evaluation of energy consumption at 1-, 3- and 6-month post-Spinal Transforaminal NeuroStimulation.

    Energy consumption will be calculated as the delivered electric current (µC per second).

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Sep 4, 2025
StartActual
Feb 10, 2026
Primary completionEst.
Feb 10, 2027
CompletionEst.
Oct 10, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07154056
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Feb 10, 2026
Primary completion
Feb 10, 2027 (estimated)
Completion
Oct 10, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Philippe Rigoard, MD, PhD
Contact
philippe.rigoard@chu-poitiers.fr
+33549443548
Manuel ROULAUD, MS, PhD
Contact
manuel.roulaud@chu-poitiers.fr
+33549443223

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion